Table 3: Secondary outcomes

Case n./age/sex BCVA 1 (RE/LE) BCVA 2 (RE/LE) DMARDs 1 DMARDs 2 Infliximab therapy Adverse effects to infliximab
1/30/M HM/1 HM/1.3 AZA/CSA AZA/ADA Suspended (loss of efficacy) no
2/39/M 0/1 0/1 CSA CSA Continued no
3/28/M 1/1 0/0 CSA CSA Continued no
4/46/F HM/HM 1.79/HM CSA - Continued no
5/23/M 0.15/0.69 0.15/0.69 AZA AZA Continued no
6/30/M 1/0 0.22/0 CSA Colch/ADA Suspended (loss of efficacy) no
7/31/M HM/0.3 HM/0.045 CSA - Continued no
8/28/F 0.15 0.22 AZA AZA Continued no
9/48/F 0/2.09 0.096/2.09 AZA/CSA - Continued no
10/64/F 1.48 HM CSA - Continued no
11/49/F 0.22/0.39 0.3/0.15 CSA/Colch AZA/Colch Continued no
12/49/M 0/0.045 0/0.045 CSA - Continued no
13/43/M 0.045/0.15 0.045/0.69 AZA/CSA AZA/ADA Suspended (loss of efficacy) no
14/61/F 0.22/0.69 0.22/0.69 CSA CSA Continued no
15/42/M 0 0 AZA/CSA CSA/ INFα Suspended (adverse effect) acute bronchitis
16/48/F 0.69 1 CSA CSA/ADA Suspended (adverse effect/loss of efficacy) acute bronchitis
17/32/M 0/0.39 0.22/1 CSA CSA/INFα Suspended (lack of effect) no
18/71/F 1/0.3 1/0.3 CSA MTX Continued no
19/65/F 0/0.3 0/0.096 AZA AZA/ Continued no
20/20/M 1.79/1.3 1/1 AZA/CSA AZA Continued no
21/26/M 0.096/0.096 0/0 AZA - Continued no
22/47/F HM/1 HM/1 AZA/CSA AZA Continued no
23/32/M 0.15 0.15 CSA - Continued no
24/28/M 0.69 0.69 AZA AZA Continued no
25/62/F 1.79/1.79 1.48/1.79 AZA/CSA AZA Continued no
26/34/M 0.096 0.096 CSA AZA Continued no
27/37/M 1.79/1.79 1.48/1.79 AZA MTX Continued no
28/56/M 0.69/1.79 1.79/2.09 CSA - Continued no
29/57/M 2.09/1 2.09/1.79 CSA Colch/ADA Suspended (loss of efficacy) no
30/32/M 0/0.096 -0.04/0.045 AZA/CSA - Continued no
31/13/M 0.39 0.39 CSA CSA/ADA Suspended (loss of efficacy) no
32/34/M 1.79/0.15 HM/0.045 CSA CSA Continued no


BCVA 1 (logMAR) and DMARDs 1 refer to data at baseline, BCVA 2 (logMAR) and DMARDs 2 refer to data at last record before beginning of the study, RE/LE: Right Eye/Left Eye, HM: Hand Movement, CS: Corticosteroids, CSA: Cyclosporin A, AZA: Azathioprine, Colch: Colchicine, MTX: Methotrexate, INFα: Interferon-α, ADA: Adalimumab